{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T12:19:32Z","timestamp":1794485972060,"version":"4.9.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001648","name":"European Foundation for the Study of Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001648","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["201907000127"],"award-info":[{"award-number":["201907000127"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"publisher","award":["202307720007"],"award-info":[{"award-number":["202307720007"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.metabol.2026.156568","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:16:05Z","timestamp":1771287365000},"page":"156568","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The early metabolic cardiac targets of empagliflozin during the development of heart failure, independent of SGLT2 inhibition"],"prefix":"10.1016","volume":"178","author":[{"given":"Sha","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"van der Made","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Tebbens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Lykidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke K.J.","family":"van Goor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus W.","family":"Hollmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina C.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"van Weeghel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bauke V.","family":"Schomakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Pieper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther E.","family":"Creemers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coert J.","family":"Zuurbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2026.156568_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156568_bb0010","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2026.156568_bb0015","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"TA","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.metabol.2026.156568_bb0020","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.HYP.11.5.416","article-title":"Effects of moderate hypertension on cardiac function and metabolism in the rabbit","volume":"11","author":"Taegtmeyer","year":"1988","journal-title":"Hypertension"},{"key":"10.1016\/j.metabol.2026.156568_bb0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/cvr\/cvr071","article-title":"Glucose metabolism and cardiac hypertrophy","volume":"90","author":"Kolwicz","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0030","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41569-025-01166-7","article-title":"Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets","author":"Mericskay","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156144","article-title":"Metabolites-mediated posttranslational modifications in cardiac metabolic remodeling: Implications for disease pathology and therapeutic potential","volume":"165","author":"Guo","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156568_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155532","article-title":"The role of histone deacetylases in cardiac energy metabolism in heart diseases","volume":"142","author":"Yu","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156568_bb0050","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1161\/CIRCRESAHA.119.315180","article-title":"Glucose 6-Phosphate Accumulates via Phosphoglucose Isomerase Inhibition in Heart Muscle","volume":"126","author":"Karlstaedt","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0055","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","article-title":"Metabolic Remodeling Promotes Cardiac Hypertrophy by Directing Glucose to Aspartate Biosynthesis","volume":"126","author":"Ritterhoff","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0060","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/cvr\/cvp414","article-title":"Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload","volume":"86","author":"Doenst","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0065","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0070","article-title":"Is boosting OXPHOS\/FAO gene pathways the final end-mechanism of SGLT2i protection?","volume":"12","author":"Hu","year":"2025","journal-title":"J Mol Cell Cardiol Plus"},{"key":"10.1016\/j.metabol.2026.156568_bb0075","article-title":"SGLT2 inhibitor upregulates myocardial genes for oxidative phosphorylation and fatty acid metabolism in G\u03b1q-mice","volume":"12","author":"Chambers","year":"2025","journal-title":"J Mol Cell Cardiol Plus"},{"key":"10.1016\/j.metabol.2026.156568_bb0080","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jare.2024.04.030","article-title":"Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression","volume":"70","author":"Zhao","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0085","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00395-024-01067-9","article-title":"Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2","volume":"119","author":"Chen","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0090","article-title":"Dapagliflozin protects against chronic heart failure in mice by inhibiting macrophage-mediated inflammation, independent of SGLT2","volume":"4","author":"Wu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.metabol.2026.156568_bb0095","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCRESAHA.124.324823","article-title":"SGLT2 Inhibitors Act Independently of SGLT2 to Confer Benefit for HFrEF in Mice","volume":"135","author":"Berger","year":"2024","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0100","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.122.061688","article-title":"Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2","volume":"147","author":"Chen","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0105","doi-asserted-by":"crossref","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s00125-022-05851-x","article-title":"Empagliflozin protects mice against diet-induced obesity, insulin resistance and hepatic steatosis","volume":"66","author":"Radlinger","year":"2023","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156568_bb0115","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1161\/CIRCULATIONAHA.116.023003","article-title":"Experimentally Increasing the Compliance of Titin Through RNA Binding Motif-20 (RBM20) Inhibition Improves Diastolic Function In a Mouse Model of Heart Failure With Preserved Ejection Fraction","volume":"134","author":"Methawasin","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0120","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007622","article-title":"Sodium Channel Remodeling in Subcellular Microdomains of Murine Failing Cardiomyocytes","volume":"6","author":"Rivaud","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2026.156568_bb0125","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10557-021-07189-9","article-title":"The Redox Modulating Sonlicromanol Active Metabolite KH176m and the Antioxidant MPG Protect Against Short-Duration Cardiac Ischemia-Reperfusion Injury","volume":"35","author":"Xiao","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.metabol.2026.156568_bb0130","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00395-024-01042-4","article-title":"Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside","volume":"119","author":"Xiao","year":"2024","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.592233","article-title":"Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases alpha-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts","volume":"7","author":"Zhang","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.metabol.2026.156568_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2022.101302","article-title":"Polar metabolomics in human muscle biopsies using a liquid-liquid extraction and full-scan LC-MS","volume":"3","author":"Schomakers","year":"2022","journal-title":"STAR Protoc"},{"key":"10.1016\/j.metabol.2026.156568_bb0145","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1038\/s41598-018-36293-4","article-title":"Correcting for natural isotope abundance and tracer impurity in MS-, MS\/MS- and high-resolution-multiple-tracer-data from stable isotope labeling experiments with IsoCorrectoR","volume":"8","author":"Heinrich","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.metabol.2026.156568_bb0150","doi-asserted-by":"crossref","first-page":"H496","DOI":"10.1152\/ajpheart.01182.2004","article-title":"Ischemic preconditioning, insulin, and morphine all cause hexokinase redistribution","volume":"289","author":"Zuurbier","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/cvr\/cvag040","article-title":"Sodium myo-inositol cotransporter-1, SMIT1, promotes cardiac hypertrophy and fibrosis in pressure overloaded mouse hearts","author":"Marino","year":"2026","journal-title":"Cardiovascular Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155818","article-title":"Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation","volume":"154","author":"Pherwani","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2026.156568_bb0165","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cmet.2015.06.021","article-title":"Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress","volume":"22","author":"Oldham","year":"2015","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156568_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.yjmcc.2021.05.016","article-title":"Metabolic remodeling precedes mTORC1-mediated cardiac hypertrophy","volume":"158","author":"Davogustto","year":"2021","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.metabol.2026.156568_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cardiores.2007.05.004","article-title":"Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart","volume":"76","author":"Sharma","year":"2007","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.metabol.2026.156568_bb0180","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.004796","article-title":"Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart","volume":"2","author":"Sen","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.metabol.2026.156568_bb0185","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1161\/CIRCRESAHA.108.189951","article-title":"Substrate-enzyme competition attenuates upregulated anaplerotic flux through malic enzyme in hypertrophied rat heart and restores triacylglyceride content: attenuating upregulated anaplerosis in hypertrophy","volume":"104","author":"Pound","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0190","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1161\/CIRCULATIONAHA.106.668665","article-title":"Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts","volume":"115","author":"Sorokina","year":"2007","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.metabol.2026.156568_bb0195","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI200524408","article-title":"Oxygen, oxidative stress, hypoxia, and heart failure","volume":"115","author":"Giordano","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2026.156568_bb0200","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/CIRCRESAHA.118.312660","article-title":"Enhanced Redox State and Efficiency of Glucose Oxidation With miR Based Suppression of Maladaptive NADPH-Dependent Malic Enzyme 1 Expression in Hypertrophied Hearts","volume":"122","author":"Lahey","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0205","doi-asserted-by":"crossref","first-page":"H422","DOI":"10.1152\/ajpheart.00219.2020","article-title":"In vivo [U-(13)C]glucose labeling to assess heart metabolism in murine models of pressure and volume overload","volume":"319","author":"Schnelle","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0210","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/nu11092092","article-title":"The emerging role of l-glutamine in cardiovascular health and disease","volume":"11","author":"Durante","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.metabol.2026.156568_bb0220","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41467-020-15640-y","article-title":"Chronic activation of hexosamine biosynthesis in the heart triggers pathological cardiac remodeling","volume":"11","author":"Tran","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.metabol.2026.156568_bb0225","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yjmcc.2012.11.008","article-title":"Metabolic effects of glutamine on the heart: anaplerosis versus the hexosamine biosynthetic pathway","volume":"55","author":"Lauzier","year":"2013","journal-title":"J Mol Cell Cardiol"},{"issue":"4","key":"10.1016\/j.metabol.2026.156568_bb0230","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cmet.2020.07.013","article-title":"Quantitative Fluxomics of Circulating Metabolites","volume":"32","author":"Hui","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156568_bb0235","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1080\/08927014.2019.1627337","article-title":"A putative LysR-type transcriptional regulator inhibits biofilm synthesis in Pseudomonas aeruginosa","volume":"35","author":"Yang","year":"2019","journal-title":"Biofouling"},{"key":"10.1016\/j.metabol.2026.156568_bb0240","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/cvr\/cvq250","article-title":"Mitochondrial SIRT3 and heart disease","volume":"88","author":"Pillai","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0245","article-title":"Sirtuin-3-mediated cellular metabolism links cardiovascular remodeling with hypertension","volume":"12","author":"Gao","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.metabol.2026.156568_bb0250","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.124.325550","article-title":"The Heart Has Intrinsic Ketogenic Capacity that Mediates NAD(+) Therapy in HFpEF","volume":"136","author":"Koay","year":"2025","journal-title":"Circ Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0255","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2026.156568_bb0260","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.metabol.2026.156568_bb0265","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12944-024-02293-9","article-title":"Empagliflozin alleviates obesity-related cardiac dysfunction via the activation of SIRT3-mediated autophagosome formation","volume":"23","author":"Luo","year":"2024","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.metabol.2026.156568_bb0270","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/CIRCULATIONAHA.115.018935","article-title":"SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction","volume":"133","author":"Lai","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0275","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.2337\/db14-1810","article-title":"SIRT3 Is Crucial for Maintaining Skeletal Muscle Insulin Action and Protects Against Severe Insulin Resistance in High-Fat-Fed Mice","volume":"64","author":"Lantier","year":"2015","journal-title":"Diabetes"},{"key":"10.1016\/j.metabol.2026.156568_bb0280","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1007\/s10557-020-07083-w","article-title":"Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells","volume":"35","author":"Uthman","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.metabol.2026.156568_bb0285","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1038\/s41598-018-23420-4","article-title":"Canagliflozin inhibits interleukin-1\u03b2-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms","volume":"8","author":"Mancini","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.metabol.2026.156568_bb0290","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.yjmcc.2008.10.025","article-title":"PGC-1alpha and ERRalpha target gene downregulation is a signature of the failing human heart","volume":"46","author":"Sihag","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0295","article-title":"The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy","volume":"5","author":"Hu","year":"2024","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.metabol.2026.156568_bb0300","doi-asserted-by":"crossref","first-page":"H597","DOI":"10.1152\/ajpheart.00731.2016","article-title":"Metabolic remodeling in hypertrophied and failing myocardium: a review","volume":"313","author":"Peterzan","year":"2017","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.metabol.2026.156568_bb0305","doi-asserted-by":"crossref","DOI":"10.1172\/JCI176708","article-title":"SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts","volume":"134","author":"Goedeke","year":"2024","journal-title":"J Clin Invest"},{"key":"10.1016\/j.metabol.2026.156568_bb0310","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehaf324","article-title":"Empagliflozin enhances metabolic efficiency and improves left ventricular hypertrophy in a hypertrophic cardiomyopathy mouse model","author":"Baka","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.metabol.2026.156568_bb0315","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","article-title":"Fatty acid oxidation enzyme gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2026.156568_bb0320","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.kint.2025.04.025","article-title":"Restoration of branched chain amino acid catabolism improves kidney function in preclinical cardiovascular-kidney-metabolic syndrome models","volume":"108","author":"Bollinger","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.metabol.2026.156568_bb0325","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.cmet.2022.09.008","article-title":"Extra-cardiac BCAA catabolism lowers blood pressure and protects from heart failure","volume":"34","author":"Murashige","year":"2022","journal-title":"Cell Metab"},{"key":"10.1016\/j.metabol.2026.156568_bb0330","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41401-023-01076-9","article-title":"Cell-autonomous effect of cardiomyocyte branched-chain amino acid catabolism in heart failure in mice","volume":"44","author":"Yu","year":"2023","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"10.1016\/j.metabol.2026.156568_bb0335","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.metabol.2026.156568_bb0340","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"10.1016\/j.metabol.2026.156568_bb0345","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/cvr\/cvae004","article-title":"Hypertrophic cardiomyopathy dysfunction mimicked in human engineered heart tissue and improved by sodium-glucose cotransporter 2 inhibitors","volume":"120","author":"Wijnker","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2026.156568_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118670","article-title":"Sodium glucose co-transporter 2 inhibitor empagliflozin prevents endothelial dysfunction induced by oscillatory shear stress","volume":"192","author":"Li","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.metabol.2026.156568_bb0355","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1161\/CIRCULATIONAHA.123.065517","article-title":"Metabolic Communication by SGLT2 Inhibition","volume":"149","author":"Billing","year":"2024","journal-title":"Circulation"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526000788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049526000788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:03:42Z","timestamp":1779109422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049526000788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":71,"alternative-id":["S0026049526000788"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156568","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The early metabolic cardiac targets of empagliflozin during the development of heart failure, independent of SGLT2 inhibition","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2026.156568","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"156568"}}